Study on the efficacy and safety of vonoprazan plus amoxicillin dual therapy versus furazolidone-containing bismuth-based quadruple therapy as rescue treatment for helicobacter pylori infection
Objective To investigate the efficacy and safety of vonoprazan plus amoxicillin dual therapy versus furazolidone-containing bismuth-based quadruple therapy as rescue treatment for Helicobacter pylori(Hp)infection.Methods A total of 120 Hp-positive patients who had failed initial treatment and were diag-nosed and treated at the outpatient clinic of this hospital between December 2020 and June 2023 were enrolled and randomly divided into groups A and B using a random number table method,with 58 and 56 patients com-pleting treatment and follow-up,respectively.Patients in group A received vonoprazan fumarate tablets plus amoxicillin capsules dual therapy,while patients in group B received rabeprazole,colloidal bismuth pectin cap-sules,amoxicillin capsules,and furazolidone quadruple therapy.Both groups were treated for 14 days.Follow-up was conducted to record medication adherence and adverse reactions in both groups.The 13 C urea breath test was performed more than 4 weeks after the end of eradication treatment to compare the Hp eradication rates between the two groups.Results Patients in group A had higher adherence and a lower incidence of ad-verse reactions compared with those in group B,with statistically significant differences(P=0.014,0.040).Hp eradication was successfully achieved in 54 patients in group A and 51 patients in group B.There were no statistically significant differences in per-protocol eradication rates and intention-to-treat eradication rates be-tween the two groups(P＞0.05).Conclusion In terms of rescue treatment options for Hp infection,there is no significant difference in Hp eradication rates between vonoprazan plus amoxicillin dual therapy and furazol-idone-containing bismuth-based quadruple therapy.However,the former regimen has higher patient adherence and a lower incidence of adverse reactions,making it a promising better option for Hp treatment.
Von Nora ShengFurazolidoneHelicobacter pyloriRemedial treatmentDual therapyQuadruple therapy
万方数据
维普
